Hepatocellular Carcinoma (HCC), Liver Transplantation
Conditions
Brief summary
This retrospective cohort study aimed to evaluate long-term oncologic outcomes after ABO-incompatible living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC). Patients who underwent LDLT between January 2012 and December 2023 at a single tertiary center were included. Outcomes of interest included overall survival and recurrence patterns, with a focus on differences in time to recurrence between ABO-compatible and ABO-incompatible recipients.
Detailed description
This study included consecutive adult patients who underwent living donor liver transplantation for hepatocellular carcinoma at the National Cancer Center, Korea. Patients were stratified according to ABO compatibility. The primary outcomes were overall survival and time to recurrence. Survival outcomes were estimated using the Kaplan-Meier method, and risk factors for recurrence were analyzed using Cox proportional hazards regression models. The study aimed to assess whether ABO incompatibility affects long-term survival and recurrence patterns following LDLT.
Interventions
None listed
Sponsors
Seoung Hoon Kim
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
• Adult patients (≥18 years) * Underwent living donor liver transplantation for HCC * Transplantation between Jan 2012 - Dec 2023
Exclusion criteria
* • Deceased donor liver transplantation * Re-transplantation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival, Recurrence-free Survival | Up to 10 years after transplantation | Time from liver transplantation until death from any cause |
Contacts
PRINCIPAL_INVESTIGATORSeoung Hoon Kim, MD, PhD
National Cancer Center
Outcome results
None listed